Compare IART & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | SPTX |
|---|---|---|
| Founded | 1989 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 951.9M | 1.1B |
| IPO Year | 1996 | 2026 |
| Metric | IART | SPTX |
|---|---|---|
| Price | $14.10 | $19.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 9 |
| Target Price | $15.67 | ★ $37.13 |
| AVG Volume (30 Days) | ★ 1.1M | 249.2K |
| Earning Date | 10-21-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.55 | N/A |
| Revenue Next Year | $1.86 | N/A |
| P/E Ratio | $73.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.70 | $15.79 |
| 52 Week High | $20.49 | $28.38 |
| Indicator | IART | SPTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 43.36 |
| Support Level | $11.96 | $18.79 |
| Resistance Level | $14.28 | $22.57 |
| Average True Range (ATR) | 0.78 | 1.47 |
| MACD | 0.20 | -0.09 |
| Stochastic Oscillator | 64.61 | 13.67 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.